Pyridine

Pyridine

SCHEMBL812392

C1CCNC1.c1ccncc1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.53
NAPRT Q6XQN6 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
ALDH1A1 P00352 2/20 0.44
CHRNB2 P17787 5/20 0.41
CHRNA4 P43681 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.37
CXCR4 P61073 1/20 0.37
PLD1 Q13393 2/20 0.34
ADRB2 P07550 1/20 0.34
NCF1 P14598 1/20 0.34
MEN1 O00255 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C19 P33261 2/20 0.32
KMT2A Q03164 2/20 0.32
POLB P06746 1/20 0.32
CHRNA7 P36544 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2A6 P11509 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL28057559 0.97 TSHR (0.50) TSHRNAPRTTDP1ALDH1A1CHRNB2
Piperidine SCHEMBL2420379 0.97 ALDH1A1 (0.50) TSHRNAPRTTDP1ALDH1A1CHRNB2
Piperidine SCHEMBL28040221 0.95 ALDH1A1 (0.47) TSHRNAPRTTDP1ALDH1A1CHRNB2
Piperidine SCHEMBL27535943 0.95 ALDH1A1 (0.47) TSHRNAPRTTDP1ALDH1A1CHRNB2
Pyridine SCHEMBL21497058 0.94 TSHR (0.60) TSHRNAPRTTDP1ALDH1A1CHRNB2
Piperidine SCHEMBL8000110 0.92 ALDH1A1 (0.45) TSHRNAPRTTDP1ALDH1A1CHRNB2
Pyridine SCHEMBL8406615 0.92 CXCR4 (0.50) TSHRNAPRTTDP1ALDH1A1CHRNB2
Pyridine SCHEMBL5210014 0.92 CXCR4 (0.50) TSHRNAPRTTDP1ALDH1A1CHRNB2
Pyridine SCHEMBL11825162 0.91
Pyridine SCHEMBL5878565 0.88 TSHR (0.41) TSHRNAPRTTDP1ALDH1A1CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110563696-B Process for preparing heteroatom-containing cyclohexene halide 蚌埠产品质量监督检验研究院 2022-05-03 CN claimed
CN-107978733-B Positive electrode for metal secondary battery, metal secondary battery including the same, and method of preparing the same 三星电子株式会社 2022-02-18 CN claimed
CN-106058311-B Electrolyte for lithium secondary battery and lithium secondary battery comprising the same 三星电子株式会社 2021-11-12 CN claimed
CN-105390744-B Composite, method of preparing the same, electrolyte comprising the same, and lithium secondary battery 三星电子株式会社 2021-10-22 CN claimed
US-10221172-B2 Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction VANDERBILT UNIVERSITY (US) 2019-03-05 US claimed
US-20180022744-A1 BENZOTHIAZOLE AND BENZISOTHIAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY 2018-01-25 US claimed
WO-2016115272-A1 BENZOTHIAZOLE AND BENZISOTHIAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY (US) 2016-07-21 WO claimed
US-8415381-B2 Heteroaryl compounds and their uses NOVARTIS AG (CH) 2013-04-09 US claimed
US-20110028492-A1 Heteroaryl Compounds and Their Uses NOVARTIS AG (CH) 2011-02-03 US claimed
US-4629490-A PLANT GROWTH REGULATORS CIBA-GEIGY CORPORATION (US) 1986-12-16 US claimed
EP-0039310-B1 PHOSPHONOMETHYLGLYCYLHYDROXAMIC ACID AND SALTS THEREOF, THEIR PREPARATION AND USE IN HERBICIDE COMPOSITIONS CIBA-GEIGY AG (CH) 1983-11-09 EP claimed
US-4414158-A Phosphonomethylglycylhydroxamic acid and novel herbicidally active salts thereof CIBA-GEIGY CORPORATION (US) 1983-11-08 US claimed
US-20230212533-A1 PRODUCTS AND METHODS FOR THE TREATMENT OF NICOTINE DEPENDENCE THE BOARD OF TRUSTEES OF WESTERN MICHIGAN UNIVERSITY 2023-07-06 US disclosed
CN-116034157-A Products and methods for treating nicotine dependence 密歇根大学董事会 2023-04-28 CN disclosed
EP-4158006-A2 PRODUCTS AND METHODS FOR THE TREATMENT OF NICOTINE DEPENDENCE The Regents of The University of Michigan (US) 2023-04-05 EP disclosed
US-11532852-B2 Composite membrane, and lithium battery including the composite membrane SAMSUNG ELECTRONICS CO., LTD. (KR) 2022-12-20 US disclosed
WO-2001029245-A2 ENZYMATIC PROCESS FOR THE RESOLUTION OF ENANTIOMERIC MIXTURES OF β-LACTAMS FLORIDA STATE UNIVERSITY (US) 2001-04-26 WO disclosed
US-4629490-A PLANT GROWTH REGULATORS CIBA-GEIGY CORPORATION (US) 1986-12-16 US disclosed
US-4414158-A Phosphonomethylglycylhydroxamic acid and novel herbicidally active salts thereof CIBA-GEIGY CORPORATION (US) 1983-11-08 US disclosed
US-4093620-A Process for producing 2-cyano N-substituted heterocyclic compounds and products produced thereby PHILIP MORRIS INCORPORATED (US) 1978-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022744-A1 BENZOTHIAZOLE AND BENZISOTHIAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION GRM4, GRIK4, GRIA4 TSHR 604/4885NAPRT 2460/4885TDP1 1490/4885
US-10221172-B2 Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction GRM4, GRIK4, GRIA4 TSHR 604/4885NAPRT 2460/4885TDP1 1490/4885
US-20110028492-A1 Heteroaryl Compounds and Their Uses CDK9, CDK19, CDK3 TSHR 2674/4885NAPRT 2237/4885TDP1 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.